ESCMID guideline for the diagnosis and treatment of biofilm infections 2014
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't
PubMed
25596784
DOI
10.1016/j.cmi.2014.10.024
PII: S1198-743X(14)00090-1
Knihovny.cz E-resources
- Keywords
- biofilm, biofilm diagnosis, biofilm infections, biofilm treatment, biofilm-associated infections, biofilm-based infections, guidelines,
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Pneumonia, Bacterial diagnosis drug therapy MeSH
- Biofilms drug effects growth & development MeSH
- Surgical Procedures, Operative MeSH
- Prosthesis-Related Infections diagnosis therapy MeSH
- Wound Infection diagnosis therapy MeSH
- Catheter-Related Infections diagnosis therapy MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Practice Guideline MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
Biofilms cause chronic infections in tissues or by developing on the surfaces of medical devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive defence mechanisms of the patient. Biofilm infections are characterized by persisting and progressive pathology due primarily to the inflammatory response surrounding the biofilm. For this reason, many biofilm infections may be difficult to diagnose and treat efficiently. It is the purpose of the guideline to bring the current knowledge of biofilm diagnosis and therapy to the attention of clinical microbiologists and infectious disease specialists. Selected hallmark biofilm infections in tissues (e.g. cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous catheters, indwelling urinary catheters, tissue fillers) are the main focus of the guideline, but experience gained from the biofilm infections included in the guideline may inspire similar work in other biofilm infections. The clinical and laboratory parameters for diagnosing biofilm infections are outlined based on the patient's history, signs and symptoms, microscopic findings, culture-based or culture-independent diagnostic techniques and specific immune responses to identify microorganisms known to cause biofilm infections. First, recommendations are given for the collection of appropriate clinical samples, for reliable methods to specifically detect biofilms, for the evaluation of antibody responses to biofilms, for antibiotic susceptibility testing and for improvement of laboratory reports of biofilm findings in the clinical microbiology laboratory. Second, recommendations are given for the prevention and treatment of biofilm infections and for monitoring treatment effectiveness. Finally, suggestions for future research are given to improve diagnosis and treatment of biofilm infections.
Department of Clinical Microbiology Rigshospitalet Copenhagen Denmark
Department of Internal Medicine 2 Julius Maximilians University Würzburg Germany
Department of Orthopaedic Surgery Hvidovre University Hospital Hvidovre Denmark
Institute for Microbiology Masaryk University and St Anne's University Hospital Brno Czech Republic
Institute of Healthcare Associated Infection University of the West of Scotland Paisley UK
Laboratoire Ecologie et Biologie des Interactions Université de Poitiers Poitiers France
Laboratory of Pharmaceutical Microbiology Ghent University Ghent Belgium
Microbial Biofilm Laboratory IRCCS Fondazione Santa Lucia Rome Italy
References provided by Crossref.org
The crafty opponent: the defense systems of Staphylococcus aureus and response measures
Rapid identification of staphylococci by Raman spectroscopy
In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin